In the U.K., one-third of patients receiving treatment with dialysis have diabetes. Guidelines from organizations representing patients with renal disease or diabetes advocate tight glycemic control in patients with end-stage renal disease, despite glucose-lowering trials having excluded these patients.
Diabetes mellitus increases the risk of chronic kidney disease (CKD), and, among dialysis patients, increases the risk of death independent of age, ethnicity, and comorbidities (1) . For diabetic patients with renal failure, The Renal Association in the U.K. suggests that all CKD, dialysis, and transplant patients with diabetes achieve a level of hemoglobin (Hb) A 1c (HbA 1c ) between 6.5 and 7.5% (48-58 mmol/mol) (2) . The National Kidney Foundation advocates a target HbA 1c level of 7.0% (53 mmol/mol), but that the target be "extended above 7.0% for patients with comorbidities" (3) . While individual trials have shown that intensive glycemic control lowers the risks of aspects of nephropathy, a meta-analysis (4) from the Cochrane protocol did not show a decrease in the occurrence of nephropathy. The authors of another meta-analysis (5), who separated manifestations of nephropathy, reported that intensive glycemic control lowers the risk of albuminuria, but not of worsening serum creatinine levels or the development of end-stage renal disease (ESRD) together. Of more direct relevance to patients who already have ESRD, the major glucose-lowering trials in diabetes on which renal guidelines base recommendations uniformly excluded patients with significant renal insufficiency. Generalizing HbA 1c target levels of 6.5-7.5% (48-58 mmol/mol) for patients with ESRD may be inappropriate, particularly given the increased risk of hypoglycemia associated with more intensive blood glucose lowering, and because of the increased prevalence of hypounawareness and cardiovascular disease in people with long-standing diabetes. Commentary has cast doubt on the safety of attempting to obtain "tight" glycemic control among patients with CKD (6) .
In the absence of evidence from clinical trials in patients with ESRD in the near future, observational evidence must guide the treatment of diabetes. Observational data relating the degree of glycemia to outcomes in patients receiving renal replacement therapy (RRT) remains relatively sparse and may vary not only as to whether an association exists, but in its reported direction. Using national data from the UK Renal Registry, we investigated longitudinally whether an association exists in individuals with diabetes between glycemia measured at the start of dialysis and subsequent mortality.
RESEARCH DESIGN AND METHODS

Definition of Glycemia
The main exposure was glycemia measured by HbA 1c levels within 6 months after the start of dialysis. If more than one value existed, we chose the value obtained within the same 3-month period of starting dialysis. All HbA 1c measurements were performed in National Health Service (NHS)-accredited laboratories. We categorized HbA 1c defining the reference category by the HbA 1c level recommended by the Renal Association, that is, an HbA 1c level of 6.5-7.4% (48-57 mmol/mol), and to which we compared categories defined by levels of ,6.5% (,48 mmol/mol), 7.5-8.4% (58-68 mmol/mol), and $8.5% ($69 mmol/mol). We also modeled HbA 1c level as a continuous variable, assuming both a linear relationship and a nonlinear relationship with log-transformed HbA 1c level as the exposure.
Definition of Outcome
Death was documented by clinicians and confirmed with national death records.
Population
The UK Renal Registry records demographic and clinical data updated quarterly on all patients receiving RRT in the U.K., extracted electronically from databases used for clinical care in centers offering hemodialysis (HD) or peritoneal dialysis (7) . Launched in 1997 with nine centers, it now receives data from all 71 centers providing RRT in the U.K., including data from centers in Northern Ireland and Scotland, which are shared with the UK Renal Registry by the Scottish Renal Registry.
The population in these analyses included diabetic patients $18 years of age with biochemical data, including an HbA 1c value, who started dialysis (either HD or peritoneal dialysis) during a 10-year period from 1 January 1997 to 31 December 2006. The patients were observed for at least 6 months until they died, were lost to follow-up, or 31 December 2009. The population included patients for whom diabetes was defined by physician diagnosis, but for whom diabetes was not necessarily coded as the primary cause of ESRD. The data set shared by the Scottish Renal Registry did not include biochemical variables, so the nine Scottish centers were excluded.
From an initial population of 7,814, we excluded patients who, within the first 6 months of follow-up, died (n = 797), were lost to follow-up (n = 21), recovered or stopped treatment (n = 36), underwent renal transplant without having started dialysis (n = 150), or underwent renal transplant having started dialysis (n = 78), leaving 6,732 individuals. We excluded other individuals who had no data on HbA 1c level (n = 3,386) or Hb level (n = 19) measured within the first 6 months of starting dialysis or who had no data on ethnicity (n = 170). This left 3,157 individuals with information on HbA 1c and Hb levels measured within 6 months of starting dialysis, age, sex, ethnicity, Hb level, mode of dialysis, year of starting dialysis, and a measure of social deprivation.
Statistical Analyses
We performed descriptive analyses of the population by level of HbA 1c , as well as by level of HbA 1c stratified by age. We tested differences across levels using Kruskal-Wallis one-way ANOVA or x 2 test. We compared the characteristics of patients included in the analyses to those excluded. We estimated the ageadjusted mortality rates using Poisson regression and number of person-years at risk by category of HbA 1c level. We performed survival analysis using proportional hazards modeling, checking for proportionality using Schoenfeld residuals. We used HbA 1c level as the main exposure, and time from 6 months from the start of dialysis to death or censoring as the outcome. We defined censoring as loss to followup, renal transplantation, or alive without transplantation. We tested for interaction defining the product between HbA 1c level by group and a binary variable for age in years (,60 or $60 years), reflecting a value approximating the median age in this population. To address the possibility of nonrandom (namely, "informative") censoring at transplant, we performed sensitivity analyses assuming instead that individuals were censored only at loss-to-follow-up or were alive at the end of the follow-up period. Last, we estimated median survival from Kaplan-Meier curves.
Potential Confounders
We adjusted for risk factors for death that were also plausibly related to glycemia. Potential confounders included age, sex, ethnicity, mode of dialysis, year of starting dialysis, cause of ESRD, and a measure of social deprivation. In addition, because anemia can affect the interpretation of HbA 1c level, we adjusted for the concentration of Hb in the blood. Ethnicity was defined as white, AfroCaribbean, South Asian, and other. Social deprivation was estimated using the Townsend Deprivation Score (a measure of material deprivation derived from postcode, and based on car and home ownership, overcrowding and unemployment) (8), with higher scores representing more deprivation. Hb (in grams per deciliter) was measured from 0 to 6 months after starting dialysis.
Returns to the UK Renal Registry from many centers are incomplete for data pertaining to BMI, blood pressure, concurrent cardiovascular disease, and timing of presentation with ESRD prior to start of dialysis, and so we excluded these variables from the analysis. Because they were not available in the registry data set, we could not control for type of diabetes, duration of diabetes, or medications used to treat diabetes.
RESULTS
The mode of dialysis in this diabetic population was predominantly HD (70%). Diabetes was recorded as the cause of renal failure for the majority of patients (85%). The median age of the population was 62 years; half of the patients were aged 50-71 years. Another limitation of this study is the degree of missing data in the main exposure, glycemia. The data for the UK Renal Registry comes from computerized data management systems aligned with renal units. Depending on local service arrangements and data sharing, blood samples for HbA 1c measurement obtained by other practitioners (e.g., including general practitioners and diabetologists) may not be transferred to the renal physicians who do not have primary responsibility for diabetes care. All patients in the NHS have a general practitioner whose services are free at the point of care, and, insofar as the patients included in this study are dialysis patients, they are, by definition, interacting with the NHS. We have previously observed that patients with missing data often have additional comorbidities (16); however, there was no difference in mortality between patients included and excluded from this study (Supplementary Table 1 ). In addition, included and excluded patients were similar with respect to Hb concentration, sex, ethnicity, mode of dialysis, and cause of renal failure, suggesting that it is possible that patients included and excluded from the study also had similar values of HbA 1c .
Other investigators have analyzed cohorts and described the association between HbA 1c level and death. In North Carolina, investigators observed a crude, but not an independent, association between HbA 1c level and mortality among 444 patients, of whom 156 died (14) . Investigators in Alberta, Canada, observed no association among 540 patients with measured HbA 1c values, 83% of whom were known to have diabetes, when the exposure was modeled either as a continuous or categorical variable, or as a baseline or a time-varying variable (12) . The investigators also evaluated blood glucose levels (as distinct from HbA 1c levels), finding no association between 
